Shire launches Natpara for Injection in US for hypocalcemia in patients with hypoparathyroidism
Due to the potential risk of osteosarcoma, Natpara is indicated only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.